Table 2 Most common adverse events irrespective of attribution
Adverse Event | MSC Group (n = 9) | Control Group (n = 9) | ||
|---|---|---|---|---|
Grade 1/2 No. (%) | Grade 3/4 No. (%) | Grade 1/2 No. (%) | Grade 3/4 No. (%) | |
Hepatotoxicity | 0 | 0 | 0 | 0 |
Renal failure | 0 | 0 | 0 | 0 |
Nausea | 0 | 0 | 0 | 0 |
Diarrhea | 0 | 0 | 0 | 0 |
Oral mucositis | 1 (11) | 0 | 0 | 0 |
Arrythmia | 0 | 0 | 0 | 0 |
Heart failure | 0 | 0 | 0 | 0 |
Hypertension | 0 | 0 | 0 | 0 |
Pericarditis | 0 | 0 | 0 | 0 |
Peripheral neuropathy | 0 | 0 | 0 | 0 |
Infections | 0 | 1 (11) | 0 | 1 (11) |
Anaphylaxis (including drug fever) | 3 (33) | 1 (11) | 0 | 0 |
Local phlebitis | 0 | 0 | 0 | 0 |
Fatigue | 0 | 0 | 0 | 0 |
Headache | 0 | 0 | 0 | 0 |
Fingernail changes | 0 | 0 | 0 | 0 |